The risk of thrombotic events is increased by coagulopathy accompanying COVID-19, in the course of which high concentrations of D-dimers, fibrinogen degradation products, fibrinogen, thrombocytopaenia, changes in activated partial thromboplastin time (APTT) and prothrombin time (PT, prothrombin time) are observed, as well as increased stability of the blood clot [12]. Here, F2 is linked to COVID-19.